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Background: Christchurch hospital is a tertiary hospital in New Zealand supported by five 
general neurologists with after-hours services provided mainly by onsite non-neurology 
medical residents. We assessed the transferrability and impact of the Helsinki Stroke 
model on stroke thrombolysis door-to-needle time (DNT) in Christchurch hospital.
Methods: Key components of the Helsinki Stroke model were implemented first in 2015 
with introduction of patient pre-notification and thrombolysis by the computed tomo-
graphy (CT) suite, followed by implementation of direct transfer to CT on ambulance 
stretcher in May 2017. Data from the prospective thrombolysis registry which began in 
2012 were analyzed for the impact of these interventions on median DNT.
results: Between May and December 2017, 46 patients were treated with alteplase, 
25 (54%) patients were treated in-hours (08:00–17:00 non-public holiday weekdays) 
and 21 (46%) patients were treated after-hours. The in-hours, after-hours, and overall 
median (interquartile range) DNTs were 34 (28–43), 47 (38–60), and 40 (30–51) minutes. 
The corresponding times in 2012–2014 prior to interventions were 87 (68–106), 86 
(72–116), and 87 (71–112) minutes, representing median DNT reduction of 53, 39, and 
47 minutes, respectively (p-values <0.01). The interventions also resulted in significant 
reductions in the overall median door-to-CT time (from 49 to 19 min), CT-to-needle time 
(32 to 20 min) and onset-to-needle time (168 to 120 min).
conclusion: The Helsinki stroke model is transferrable with real-world resources and 
reduced stroke DNT in Christchurch by over 50%.
Keywords: thrombolysis, door-to-needle, delay, resource, stroke
inTrODUcTiOn
Intravenous thrombolysis with tissue plasminogen activator (tPA)—alteplase—is the current standard 
treatment for ischemic stroke within 4.5 h of symptom onset (1). The benefit of tPA diminishes with 
treatment delay (1, 2); every minute delay to treatment is associated with nearly two disability free health 
days lost (2). Successful reduction in stroke treatment times through implementing systematic 
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thrombolysis protocol has been reported in stroke centers around 
the world (3–5) with the most rapid stroke treatment reported 
to-date achieved in Helsinki (6). The Helsinki stroke model 
consisted of 12 interventions aimed at reducing treatment delays 
prior to thrombolysis and the adaptation of this model resulted in 
18-min reduction in thrombolysis delay to 25 min in Melbourne 
within 4 months (7). The American Heart Association/American 
Stroke Association Target: Stroke initiative also recommended a 
similar 10-step intervention (8) aimed at reducing door-to-needle 
times (DNT) and resulted in nearly 80% relative increase in the 
proportion of stroke tPA administered within 60 min of hospital 
arrival (9).
The ethos of these models focuses on patient pre-notification, 
rapid clinical assessment, image acquisition, and treatment 
administration in a chain of responses requiring parallel pro-
cessing by on-site radiology and neurology personnel. This is 
possible in healthcare settings with access to 24/7 on-site spe-
cialist personnel, which is not available in hospitals throughout 
New Zealand. The transferrability of thrombolysis models such 
as the Helsinki model in this setting is uncertain. The aim of this 
paper is to report the transferrability and impact on DNT of the 




Christchurch Hospital is a government funded tertiary hospital 
located in Christchurch city in the South Island of New Zealand. It 
provides hospital care to the Canterbury region with a catchment 
population of ~500,000 and is the second largest public hospital 
by catchment population in New Zealand. Christchurch Hospital 
admits approximately 600 ischemic stroke patients annually to a 
dedicated 15-bed acute stroke unit and is the only hospital in the 
South Island with capacity for endovascular clot retrieval. Most 
stroke patients are ultimately cared for by the stroke rehabilita-
tion physician in the stroke unit, while stroke patients consid-
ered for thrombolysis or endovascular clot retrieval are admitted 
under the neurology bed card within the stroke unit for the first 
24–48 h. The neurology team consists of five general neurologists 
with two neurology trainee residents and one rotating medical 
resident. The residents participate in a 1 in 7 after-hours on-
call roster (16:00–22:30) with residents from nephrology and 
infectious diseases. The night roster (22:30–08:00) is shared 
by also the medical specialty residents together with rotating 
internal medicine residents. The after-hours on call resident is 
responsible for clinical management of neurology, nephrology, 
and infectious diseases patients. The neurologists share a 1 in 
4 on-call roster and are available by phone 24/7 and are gener-
ally on site until 17:00 and for this reason we consider business 
hours to be between 08:00 and 17:00 on non-public holiday 
weekdays. The after-hours stroke cover is provided mainly by 
non-neurology residents and because of this, a 4-monthly stroke 
pathway presentation has been held to coincide with changeover 
of rotating residents. Further individual feedback sessions are 
available. Additionally, there is an ongoing annual education and 
update on the acute stroke service to the St. John Ambulance 
paramedics.
The Thrombolysis registry and 
institutional approval
A prospective stroke thrombolysis registry was started in 
2012. The registry contains basic demographic and clinical 
information for patients receiving tPA. National Institutes of 
Health Stroke Scale (NIHSS) was available in most patients and 
retrospectively calculated for patients missing this variable. The 
registry collected a number of time metrics, including symptom 
onset time, hospital arrival time, time of imaging, and throm-
bolysis. For inpatient strokes, the time stroke page was initiated 
and was used as the arrival time. DNT was taken as the time 
taken in minutes from recorded arrival time at the emergency 
department (ED) to the recorded time of tPA bolus administra-
tion. Door to computed tomography (CT) time was defined as 
time taken in minutes from arrival time in ED to completion of 
non-contrast CT images. Stroke mimics who were thrombolysed 
were also included in the present analysis. Symptomatic intrac-
erebral hemorrhage was defined as per Safe Implementation of 
Thrombolysis in Stroke-Monitoring Study (SITS-MOST) (10). 
Long-term outcome data were unavailable as clinical follow up 
was not routine.
For the present study, we included all consecutive patient 
receiving tPA for presumed acute ischemic stroke between 
January 2012 and December 2017 even if the final diagnosis was 
a stroke mimic. We excluded two inpatient strokes with missing 
stroke page time.
The thrombolysis registry forms part of the Christchurch 
Stroke registry study and the prospective National New Zealand 
Thrombolysis Registry as mandated by the Ministry of Health 
and has approval from the national Health Disability Ethics 
Committee and Christchurch Hospital research office. As this 
is a quality improvement, observational registry without devia-
tion from routine care or additional patient contact, consent for 
inclusion into this analysis was not required by the New Zealand 
research legislation, allowing for inclusion of all consecutive 
patients.
Treatment criteria
Acute stroke thrombolysis was introduced in Christchurch 
hospital in April 2002 for patients presenting within 3  h of 
symptoms onset or from last known well time. The treatment 
time window was extended to 4.5 h in 2009 following publica-
tion of the third European Cooperative Acute Stroke Study 
(ECASS III) (11). We have no age restriction but restricted tPA 
for patients with good pre-morbid functional status (pre-stroke 
modified Rankin Scale score 0–3). There is no NIHSS restric-
tion but treatment is generally not offered to patients with 
minor strokes symptoms with NIHSS ≤4 with the exception of 
isolated homonymous hemianopia. In patients on warfarin, tPA 
is given to patients with an international normalized ratio ≤1.5. 
In patients known to be on dabigatran, idarucizumab is given 
prior to tPA. Other standard contraindications apply as per 
best practice guidelines (12). Informed consent was provided 
TaBle 1 | The new stroke thrombolysis model in Christchurch Hospital.
christchurch thrombolysis model—modified from the 
helsinki stroke model (6)
Stroke patient 
pre-notification
St. John Ambulance paramedic pre-notifies ED triage room 
with patient clinical and demographic details including 
national hospital index number unique to individual patient. 
An estimated time of arrival is given. CT radiographer, 
neurology resident, and stroke nurse are paged via “Code 
Stroke” call to switchboard
Medical history Patient electronic medical record, including general 
practitioner, next of kin details, laboratory results, and a 
South Island wide PACS system is examined. Next of kin 
contacted for collateral history prior to arrival as required
Direct to CT Upon arrival, the patient is examined on the ambulance 
trolley to determine eligibility for thrombolysis. If deemed, 
eligible patient is transported to the CT suite located 
on first floor of the hospital. Electronic ordering of CT is 
performed by stroke nurse or ED physician
Intravenous line/
laboratory testing
Patients usually have 18-gauge antecubital fossa 
intravenous line, otherwise this is inserted on arrival in ED. 
Bloods drawn on arrival or on CT table. Blood results not 




Point-of-care INR available. Idarucizumab stored in ED 
fridge and taken with patient to CT suite and administered 
there prior to thrombolysis
tPA in CT suite Bolus given on table, but usually in a clinical cubical 
adjacent to the CT scanner
Regular paramedic/
resident education
Four monthly stroke model education session with rotating 
registrars. Annual formal paramedic education and update 
on stroke statistics
CT, computed tomography; ED, emergency department; INR, international normalized 
ratio; PACS, picture archiving and communication system; tPA, tissue plasminogen 
activator.
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verbally by the patient or next of kin. In the situation where 
a patient could not consent and the next of kin could not be 
contacted, a medical decision would be made by the neurologist 
to proceed with treatment.
christchurch hospital stroke 
Thrombolysis Model
Previous Acute Stroke Model
Prior to 2015, acute stroke patients were selectively pre-notified 
to ED triage by the St. John Ambulance paramedic if a signifi-
cant deficit was evident. However, the acute stroke team was not 
notified until after ED physician assessment. The stroke team 
then assessed the patient in ED prior to requesting CT scan, 
which is the imaging modality of choice for acute stroke at our 
hospital. The CT suite is located on the first floor of the hospital 
and the stroke patient was not routinely given an immediate pri-
ority for imaging. Following imaging if the patient was deemed 
eligible for thrombolysis the patient was transferred to the acute 
stroke unit located also on the first floor, where the tPA was 
administered.
New Acute Stroke Model
Due to median DNT of more than 60 min even during business 
hours, an effort was made to adopt the key components of the 
Helsinki Stroke Thrombolysis model (6). In January 2015, a 
“Code Stroke” pre-notification pathway was introduced where a 
page was made to the acute stroke team initiated by ED triage 
upon paramedic notification of an incoming stroke patient. The 
page was also received by the CT radiographer, who was encour-
aged to stop processing further non-urgent CT requests until 
after the imaging of stroke patient had completed. The stroke 
team assessed the patient in the ED cubicle to determine if the 
patient had a treatable neurological deficit. If the patient had a 
treatable deficit, a scan request was sent and patient was taken for 
CT scanning. Because of resource constraints and in agreement 
with radiology, only patients deemed suitable for intervention 
(thrombolysis or endovascular clot retrieval) would proceed with 
immediate CT imaging. Imaging was immediately interpreted 
by the acute stroke team in consultation with onsite radiologist 
or radiology resident. Although multimodal imaging with CT 
angiography and perfusion was available, it was not performed 
in most patients under the old stroke model and the decision 
to administer alteplase was made after non-contrast imaging. 
In early 2016, CT perfusion and angiography were added to the 
acute stroke imaging protocol and thrombolysis was usually 
initiated after completion of all advanced imaging. Thrombolysis 
is administered in a clinical cubicle within the radiology suite 
although bolus administration on the CT table prior to advanced 
imaging is encouraged.
In May 2017 following consultation and agreement with ED, 
St. John Ambulance and radiology, the final step in the new 
thrombolysis model was introduced. The main change was for 
patient to be assessed on the ambulance stretcher in an ED bed 
cubicle immediately after arrival and if deemed a thrombolysis 
candidate the patient is transferred directly to CT on the ambu-
lance stretcher.
The St. John Ambulance paramedics are encouraged to insert 
an 18-gauge intravenous line in the antecubital fossa prior to 
arrival. Blood testing was performed in all patients but contrast 
imaging and tPA would proceed without waiting for laboratory 
results in most cases. In patients anticoagulated with warfarin, 
point-of-care international normalized ratio testing was avail-
able. In patients known to be on dabigatran, our departmental 
policy is to administer the reversal agent idarucizumab in the 
CT suite prior to thrombolysis without waiting for coagulation 
laboratory results to avoid treatment delay. Idarucizumab is kept 
in a drug room within ED and can be taken with patient to the CT 
suite or retrieved from ED by the stroke nurse once a decision to 
thrombolyse has been made. The “Code Stroke” pathway is only 
available between 08:00 and 22:30 as immediate CT during over-
night is not available due to the CT radiographers operating on a 
call-back roster system. Table 1 summarizes the key components 
of the current Christchurch Hospital stroke thrombolysis model.
statistical analysis
We analyzed the impact of the change to the stroke thrombolysis 
model by comparing time metrics achieved in the three epochs 
during the staged introduction of the new thrombolysis model—
(1) the pre-intervention period (2012–2014), (2) following 
introduction of code stroke pre-notification system (2015–2017 
TaBle 2 | Baseline characteristics, time to imaging, use of multimodal imaging, and idarucizumab in thrombolysed patients at Christchurch Hospital.
Total age national institutes of health stroke scale Door-to-imaging (minutes) Multimodal imaging Dabigatran reversal
2012 23 72 (65–81) 16 (9–21) 48 (40–57) 1 (4%) 0
2013 39 73 (58–82) 13 (8–20) 48 (40–89) 2 (5%) 0
2014 28 80 (64–87) 17 (11–21) 53 (43–64) 1 (4%) 0
2015 43 73 (60–81) 8 (5–18) 46 (36–57) 6 (14%) 2 (4.7%)
2016 55 73 (61–81) 11 (6–20) 30 (24–42) 32 (58%) 4 (7.3%)
2017 67 75 (67–83) 10 (5–17) 20 (15–27) 61 (91%) 7 (10.4%)
Total 255 74 (62–82) 13 (7–20) 39 (24–53) 103 (40%) 13 (5%)
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April), and (3) full implementation of new stroke model following 
introduction of “direct to CT” transfer (May–December 2017). 
We reported for each epoch the overall, in-hours (08:00–17:00 
non-public holiday weekdays) and after-hours time metrics. 
We analyzed the change in treatment and imaging time metrics 
between pre-interventional period and following the full imple-
mentation of the new stroke model. We included patients treated 
overnight (22:30–08:00), where the acute stroke model was non-
operational, in the after-hours statistics. The annualized overall 
and in-hours DNT during the study period were plotted graphi-
cally to illustrate the changing trend overtime. Additionally, the 
impact of advanced imaging and stroke severity on the overall 
DNT over the years was also analyzed.
Where appropriate, all data pertaining to the NIHSS, age, 
and treatment delays were presented as median with inter-
quartile range, grouped by year to demonstrate trends in time. 
Comparison of groups was analyzed using independent samples 
Mann–Whitney U or Kruskal–Wallis tests. A two-sided p-value 
<0.05 was considered statistically. Analyses were performed 
using IBM SPSS 23 software (IBM Corp., Armonk, NY, USA).
resUlTs
Patient characteristics and Treatment 
numbers
There was a progressive increase in the number of thrombolysed 
stroke patients each year (Table 2) and in the 2017 calendar year 
67 patients were given tPA representing a threefold increase 
compared to 2012. A total of 255 patients were included in 
the analysis. Over time there were no significant differences 
in the age of thrombolysed patient (p  =  0.278) with a trend 
toward lower NIHSS (p = 0.052). The use of advanced imaging 
also increased over the years and was almost routine in 2017, 
performed in 91% of tPA patients. Idarucizumab was given to 
reverse the anticoagulant effects of dabigatran prior to throm-
bolysis in seven (10.4%) patients in 2017 with median DNT of 
40 min.
Symptomatic intracerebral hemorrhage occurred in 10 (3.9%) 
patients during the study period, with 1 (2.1%) case of SICH 
observed in the 8  months between May and December 2017 
following full implementation of the new stroke model. A stroke 
mimic was diagnosed in 8 (3.1%) patients (five with non-organic 
functional symptoms, two with migraine, and one related to 
epileptic seizure). The stroke mimic treatment rate in patients 
without prior multimodal CT was 4.6% (7/152) compared to 
1.0% (1/103) with pre-treatment advanced imaging.
reduction in Treatment Metrics Over 
Time
There was progressive reduction in DNT, since 2012 with the 
largest reduction seen in the in-hours DNT from 87 (68–106) 
minutes in the pre-intervention period to 34 (28–43) minutes 
after full implementation of the new stroke model (p  <  0.01) 
(Figure 1; Table 3). The overall median DNT time also reduced 
from 87 (71–112) minutes to 40 (30–51) minutes (Figure  2; 
Table 3), while the after-hours DNT went down to 47 (38–60) 
minutes from 86 (72–116) minutes (p  <  0.01). The overnight 
median DNT was relatively unchanged from 87 min in the pre-
intervention period to 78 min in with the new stroke model. The 
proportion of patients treated within 60 min of hospital arrival 
also increased from 12% in the pre-intervention period to 79% 
in 2017.
impact of advanced imaging and stroke 
severity on Treatment Time
Multimodal CT may have resulted in DNT delay in 2013 and 2014 
based on a small number of patients with pre-treatment advanced 
imaging (Table 1; Figure 3). However, since 2015 pre-treatment 
multimodal CT did not result in a delay in DNT (Figure 3). More 
severe strokes (NIHSS ≥10) were initially associated with a faster 
DNT, but this difference diminished over time with no difference 
in treatment times in 2017 (Figure 4).
reduction in Other Time Metrics
There were also significant reductions in door-to-CT times and 
CT-to-needle times as shown in Table 3. In the final 8 months of 
2017 after full implementation of the new stroke model the overall 
median door-to-CT time was 19 (11–24) minutes and the CT-to-
needle time was 20 (14–31) minutes, representing reduction of 
30 and 12  min, respectively compared with pre-intervention 
period (all p-values <0.01). The overall median onset to treat-
ment time was also reduced from 168 (145–195) minutes in the 
pre-interventional period to 120 (87–155) minutes (p < 0.01) in 
2017 (Figure 5; Table 3).
DiscUssiOn
We have demonstrated that the key components of the Helsinki 
stroke thrombolysis model are transferrable with “real-word” 
resources and reduced median in-hours DNT from 87 to 34 min. 
The reduced stroke treatment delay was achieved despite increas-
ing routine use of advanced imaging and administration of 









Door-to-needle 87 (68–106) 61 (41–83) 34 (28–43) <0.01
Door-to-computed tomography (CT) 48 (38–67) 35 (24–47) 17 (11–20) <0.01
CT-to-needle 36 (16–49) 19 (13–33) 18 (10–24) <0.01
Onset-to-needle 160 (125–195) 122 (96–162) 101 (80–140) <0.01
after-hours
Door-to-needle 86 (72–116) 65 (52–84) 47 (38–60) <0.01
Door-to-CT 50 (41–65) 35 (25–50) 22 (15–32) <0.01
CT-to-needle 31 (20–50) 28 (19–41) 24 (17–33) 0.24
Onset-to-needle 170 (147–195) 135 (115–160) 123 (105–186) <0.01
Overall
Door-to-needle 87 (71–112) 63 (48–84) 40 (30–51) <0.01
Door-to-CT 49 (40–65) 35 (24–48) 19 (11–24) <0.01
CT-to-needle 32 (20–49) 26 (15–37) 20 (14–31) <0.01
Onset-to-needle 168 (145–195) 130 (107–160) 120 (87–155) <0.01
FigUre 1 | In-hours median door-to-needle time in minutes.
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idarucizumab to a significant minority of thrombolysed patients 
on dabigatran. Similar significant reductions in DNT were made 
after-hours despite leaving running of the “Code Stroke” mostly 
to non-neurology medical residents.
Previous studies have already reported significant reductions 
in stroke DNT by having an organized thrombolysis pathway (3). 
Adaptation of the Helsinki stroke model to the Royal Melbourne 
Hospital in Australia resulted in an 18-min reduction in the in-
hour DNT time in just 4 months (7). In the United States, the 
implementation of the American Heart Association/American 
Stroke Association national quality improvement initiative Target: 
Stroke—resulted in an increase in the proportion of tPA initiated 
within 60 min of hospital arrival from 30 to 53% in 1030 Get With 
the Guidelines—Stroke hospitals (8, 9). The 10 key best practice 
key strategies in the Target: Stroke initiative share important simi-
larities with the Helsinki Stroke model with emphasis on hospital 
pre-notification, rapid imaging acquisition, clinical assessment, 
and tPA administration (6, 8). In other single centers in Europe, 
Canada, and the United States, DNT reductions of up to 63 min 
have been reported by adopting similar systematic acute stroke 
thrombolysis pathway (4, 13–17).
There were also significant reductions in other measured time 
metrics, with reductions in door-to-CT and CT-to-needle times 
by 61% and 38%, respectively. The overall onset-to-needle time also 
FigUre 4 | Stroke severity and treatment delays. Trends in door-to-needle 
time stratified by stroke severity. NIHSS, National Institutes of Stroke Scale 
Score.FigUre 3 | Multimodal imaging and treatment delays. Trends in door-to-
needle time for patients treated with (n = 87) and without (n = 147) prior 
multimodal imaging. Abbreviations: CTA, computed tomography angiogram; 
CTP, computer tomography perfusion.
FigUre 2 | Overall median door-to-needle time in minutes.
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reduced to an overall median of 120 (87–155) minutes from 168 
(145–195) minutes similar to reported else where (6, 7, 9, 14). It is 
possible that the 30-min reduction in door-to-CT time may have 
enabled treatment of additional patients presenting late in the 
treatment window, however, it is clear that the increased number 
of patients treated over the study period is not attributable to 
late time-window treatments as the onset to treatment time has 
decreased. The increased enthusiasm for stroke intervention with 
endovascular clot retrieval (18) and recent “FAST” public aware-
ness campaigns by the Stroke Foundation of New Zealand are 
likely to have contributed to increased presentation of treatment 
eligible patients.
The main difference between our results and those published is 
the availability of on-site neurology residents. Most these centers 
FigUre 5 | Trends in median door-to-imaging, imaging-to-treatment, and onset-to-treatment times. Annual median onset to treatment (green line), door-to-imaging 
(blue line), and imaging-to-treatment (red line) times in minutes.
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have reported dedicated 24/7 (4–6, 13–17) on-site specialty 
neurology/stroke team in contrast to the set up at our hospital, 
where neurology on-site resident support is limited mainly to 
business hours. Although an on-site resident is available 24/7, 
the after-hours medical resident is additionally responsible for 
managing nephrology and infectious diseases patients in addi-
tion to acute neurology duties. Our setup is similar to other New 
Zealand centers where in 2015–2016 the median DNT was 70 
(52–97) minutes and the median onset-to-needle time was 150 
(119–195) minutes (19).
The use of advanced imaging prior to treatment resulted in 
a 20-min delay to treatment times in Helsinki (6). However, 
based on our experience, advanced imaging did not result in an 
additional delay to treatment. This is likely due to practice effect 
similar to the reported experience in Melbourne (7). Although 
giving tPA bolus after non-contrast imaging prior to advanced 
imaging would reduce DNT further, advanced imaging provides 
the on-call neurologists with diagnostic confidence particularly 
in patients presenting after hours. Our stroke mimic treatment 
rate (1.0%) in patients with pre-treatment multimodal CT was 
comparable to that reported in Helsinki (1.4%) and Melbourne 
(2.0%), where patients are generally reviewed physically by expert 
stroke neurologists (6, 7).
An important component of this model is regular education 
of non-neurology residents and St. John Ambulance paramed-
ics. Regular formal 4-monthly feedback education sessions have 
been provided to rotating medical residents in addition to annual 
paramedic update on the Stroke pathway. Additional individual 
resident feedback sessions were also available throughout the 
year. In a study by Ruff et al. a formal case-based clinical “boot 
camp” for incoming junior neurology residents resulted in 25 min 
DNT reduction in patients managed by junior staff (20). Other 
centers have also incorporated regular feedback and education 
sessions as an ongoing feature of the stroke pathway (5, 14, 21). 
Our emphasis to the rotating residents is to contact the on-call 
neurologist early for all cases particularly in cases with diagnostic 
uncertainty adopting the “if in doubt, call out” mantra.
International best practice guidelines (12, 22) have recom-
mended DNT of less than 60 min, with the Canadian guidelines 
recommending a 30-min median DNT target (22). Although our 
current results do not meet the 30-min DNT target, it is likely 
that with further practice, increasing familiarity and confidence 
with the pathway the DNT will be reduced further. We addition-
ally anticipate DNT would be reduced by at least 5 min with the 
planned relocation of the CT suite from the first floor to the ED 
toward the end of 2018. This is likely also to reduce any delays 
associated with retrieving idarucizumab from the ED drug room 
for dabigatran-treated patients. Additionally our after-hours DNT 
was negatively influenced by non-operation of the stroke model 
overnight and the call-back roster system for CT radiographers. 
The after-hours DNT is likely to reduce further when immediate 
CT access is 24/7.
The main strength of this study is that our center is a general 
hospital, and acute stroke is managed by general ED, radiology, 
and neurology departments, without specialized stroke staff. Our 
results suggest that the key elements of thrombolysis models, 
such as the Helsinki Stroke model are transferrable to health set-
tings with limited or “real world” resources. The main limitation 
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of our data is that they are acquired from a single center: actual 
results from similar hospitals may vary according to local circum-
stances. Nonetheless, our results may actually under-estimate the 
impact of the new stroke model on DNT as the DNT is likely to 
reduce further with practice and the relocation of the CT suite. 
One further limitation is that we do not have long-term outcome 
data, so the impact of shorter DNT on patient outcome cannot be 
determined. However, it is likely that the patient outcomes would 
replicate that reported in literature (1).
In conclusion, we have demonstrated the transferrability of 
the Helsinki Stroke thrombolysis model to a large volume general 
hospital, reducing the median in-hours DNT to 34  min. Our 
results should encourage other thrombolysis capable hospitals 
to consider implementing similar stroke models to reduce stroke 
treatment delay and improve patient outcome.
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